Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Acquired drug resistance and drug toxicity are key challenges when using these drugs. We investigated whether vemurafenib toxicit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Dooley, Andrew J., Gupta, Avinash, Bhattacharyya, Madhumita, Middleton, Mark R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2014
Konular:
Reviews
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4206651/
https://ncbi.nlm.nih.gov/pubmed/25364391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014548187
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller